Onkologie. 2012:6(4):205-208

Recent advances in treatment of bone sarcomas

Peter Múdry, Lucia Kútniková, Danica Zapletalová
Klinika dětské onkologie LF MU a FN Brno, Dětská nemocnice, Brno

At present, therapy success in bone sarcoma is significantly better compared to historical cohorts, with 60–70 % overall survival. Unfortunately,

no sufficient progress in better survival of patients with relapsed and refractory bone sarcomas during last twenty years has

been observed. Here we review targeted therapeutics in bone sarcomas being under investigation that may bring chance to patients

suffering from relapsed and chemoresistant bone sarcomas. A majority of the targeted drugs are given as part of phase 1 or 2 studies.

Separately, recent successful findings of efficacy of denosumab in treatment of giant bone cell tumor are described.

Keywords: sarcoma, targeted therapy, angiogenesis, giant bone cell tumor, metronomic therapy

Published: October 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Múdry P, Kútniková L, Zapletalová D. Recent advances in treatment of bone sarcomas. Onkologie. 2012;6(4):205-208.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zapletalova D, André N, Deak L, et al. Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience. Oncology 2012; 82: 249-260. Go to original source... Go to PubMed...
    2. Fuchs B, Inwards CY, Janknecht R. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin Cancer Res 2004; 10: 1344-1353. Go to original source... Go to PubMed...
    3. Payvandi F, Wu L, Haley M, et. al. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol. 2004; 230: 81-88. Go to original source... Go to PubMed...
    4. Wachsberger PR, Burd R, Cardi C, et al. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys 2007; 67: 1526-1537. Go to original source... Go to PubMed...
    5. Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2008; 26: 399-405. Go to original source... Go to PubMed...
    6. Tolcher AW, Rothenberg ML, Rodon J, et al. A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol 2007; 25 abstrakt: 3002. Go to original source... Go to PubMed...
    7. Aplenc R, Blaney SM, Strauss LC, et al. Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I Consortium. J Clin Oncol 2011; 29: 839-844. Go to original source... Go to PubMed...
    8. Sleijfer S, Papai Z, Cesne AL, et al. Phase II study of pazopanib (GW786034) in patients with relapsed or refractory soft tissue sarcoma (STS). J Clin Oncol 2007; 25(Suppl 18): 10031. Go to original source...
    9. Houghton P, Morton C, Maris J, et al. Pediatric preclinical testing program (PPTP) evaluation of the Aurora A kinase inhibitor MLN8237. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008.
    10. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005; 225: 1-26. Go to original source... Go to PubMed...
    11. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010; 363: 1727-1733. Go to original source... Go to PubMed...
    12. Xia SJ, Pressey JG, Barr FG. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 2002; 1: 97-104. Go to original source... Go to PubMed...
    13. Zhang P, Yang Y, Zweidler-McKay PA, et al. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res 2008; 14: 2962-2969. Go to original source... Go to PubMed...
    14. Tolcher AW, Mikulski SM, Messersmith WA. A phase I study of RO4929097, a novel gamma secretase inhibitor, in patients with advanced solid tumors. 2010 ASCO Annual Meeting. J Clin Oncol 2010; 28(Suppl 15): 2502. Go to original source...
    15. Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005; 65: 2406-2411. Go to original source... Go to PubMed...
    16. Pencreach E, Guerin E, Nicolet C, et al. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through kooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clin Cancer Res 2009; 15: 1297-1307. Go to original source... Go to PubMed...
    17. Hingorani P, Zhang W, Lin J, Liu L, Guha C, Kolb EA. Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts. Cancer 2010; 117: 1764-1774. Go to original source... Go to PubMed...
    18. Mita AC, Sankhala K, Sarantopoulos J, et al. A phase II study of intravenous REOLYSIN (wild-type reovirus) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung. In: Conective Tissue Oncology Society Annual Meeting, Miami 5. 11. 2009. Go to original source...
    19. Schelman WR, Kolesar J, Schell K, et al. A phase I study of vorinostat in combination with bortezomib in refractory solid tumors. Journal of Clinical Oncology 2007; 25: 3573. Go to original source...
    20. Thomas D, Henshaw R, Skubitz K, et. al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010; 11: 275-280. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.